APPLICATION OF PHOTODYNAMIC THERAPY IN COMPLEX TREATMENT OF PATIENTS WITH MALIGNANT NEOPLASMS OF PANCREAS AND BILIAR TRACT. REVIEW


Cite item

Full Text

Abstract

Data from the global oncology statistics shows that pancreatic cancer is at the 4th place in the world for mortality in men and women, having the lowest five-year life expectancy among gastrointestinal tumors with an average median survival of no more than 6 months. Along with it, malignant neoplasms of the biliary tract are rare in the frequency of occurrence of the nosological group of diseases, which, however, are on the second place in terms of the level of malignancy among the neoplasms of the liver. Both nosologies in the vast majority are not subject to radical treatment, being the object of palliative treatment due to late diagnosis. Despite the establishment of new medical technologies, the main method of treating of these nosologies remains surgical. However, at the time of detection and diagnosis less than 20% of patients have a resectable process, and, moreover, even patients with a resectable tumor are often not subjected to radical surgical treatment due to dissemination of the tumor at the time of surgery, which reduces the postoperative five-year survival of this cancer: 25-30% in patients without metastases to regional lymph nodes and about 10% in patients with metastases to regional lymph nodes. Due to the low efficiency of the surgical method, there are searched new methods of complex treatment, new drugs and chemotherapy regimens, as well as radiotherapy regimens, however, with the improvement of methods for diagnosing cancer in the past 20-25 years, neither the prognosis nor survival of patients nor the percentage of early diagnosis of cancer of the pancreas did not significantly improve. A new and promising method for the treatment of malignant neoplasms of the pancreas and the biliary tract is photodynamic therapy, the undoubted advantage of which is low toxicity, selective effect only on cancer cells at the fundamental level, contributing depending on the duration of exposure to their autophagy, apoptosis or necrosis. And, although PDT has drawbacks connected with side effects of PDT, such as gastrointestinal bleeding, obstruction of the duodenum and hemorrhagic pancreonecrosis, and with insufficient knowledge and lack of clear recommendations, but the PDT method is certainly a promising method in both radical and in palliative complex therapy of malignant neoplasms of the pancreas and biliary tract, which requires further study.

About the authors

A. E Tseimakh

Altai State Medical University of Ministry of Health Russia

656038, Barnaul, Russia

A. F Lazarev

Altai State Medical University of Ministry of Health Russia; Altai branch of Russian Cancer Research Center named after N.N. Blokhin of Ministry of Health Russia

656038, Barnaul, Russia; 656049, Barnaul, Russia

V. A Kurtukov

State hospital №5

Barnaul, 656045, Barnaul, Russia

M. E Tseimakh

Altai State Medical University of Ministry of Health Russia

656038, Barnaul, Russia

Ia. N Shoykhet

Altai State Medical University of Ministry of Health Russia

656038, Barnaul, Russia

References

  1. Yeo TP. Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma. Semin. Oncol. 2015; 42: 8-18.
  2. Клинические рекомендации. Рак поджелудочной железы. [Еlectronic resource]. Ассоциация онкологов России - 2017. 36 с. Access mode: http://oncology-association.ru/files/clinical-guidelines_adults/rak_podzheludochnoy_zhelezy.pdf
  3. Wei Li, Qingyong Ma, and Erxi Wu Perspectives on the Role of Photodynamic Therapy in the Treatment of Pancreatic Cancer. International Journal of Photoenergy. 2012; Article ID 637429: 9.
  4. Каприн А.Д., Старинский В.В., Петрова Г.В., ред. Состояние онкологической помощи населению России в 2017 году. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИРЦ» Минздрава России; 2018. 236 с.
  5. Evan L. Fogel, Safi Shahda, Kumar Sandrasegaran et al. A Multidisciplinary Approach to Pancreas Cancer in 2016: A Review. Am. J. Gastroenterol. 2017; 112 (4): 537-54.
  6. Alette Ruarus, Laurien Vroomen, Robbert Puijk et al. Locally Advanced Pancreatic Cancer: A Review of Local Ablative Therapies. Cancers. 2018; 10, 16: 1-18.
  7. Benjamin Meier and Karel Caca. Endoscopic and Photodynamic Therapy of Cholangiocarcinoma. Visc. Med. 2016; 32 (6): 411-3.
  8. Клинические рекомендации Билиарный рак. [Еlectronic resource] Ассоциация онкологов России - 2017. 37 с. Access mode: http://oncology-association.ru/files/clinical-guidelines_adults/rak_zhelchevyvodyashey_sistemy.pdf
  9. Gillen S., Schuster T., zum Büschenfelde C.M. et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7:e1000267
  10. Evans D.B., Varadhachary G.R., Crane C.H. et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J. Clin. Oncol. 2008; 26: 3496-502
  11. Loehrer P.J., Sr, Feng Y., Cardenes H.R. et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J. Clin. Oncol. 2011; 29: 4105-12. [PMC free article]
  12. Hammel P., Huguet F., Van Laethem J.-L. et al. Comparison of chemo-radiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: final results of the international phase III LAP 07 study. J. Clin. Oncol. 2013; 31(Suppl) abstr LBA4003.
  13. Chauffert B., Mornex F., Bonnetain F. et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann. Oncol. 2008; 19: 1592-9
  14. Burris H.A., 3rd, Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin. Oncol. 1997; 15: 2403-13
  15. Conroy T., Desseigne F., Ychou M. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011; 364: 1817-25
  16. Faris J.E., Blaszkowsky L.S., McDermott S. et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. 2013; 18: 543-8. [PMC free article]
  17. Katz M.H.G., Shi Q., Ahmad S.A. et al. Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): initial results from Alliance Trial A021101. J. Clin. Oncol. 2015; 33 (Suppl) abstr 4008.
  18. Gourgou-Bourgade S., Bascoul-Mollevi C., Desseigne F., et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J. Clin. Oncol. 2013; 31: 23-9
  19. Oettle H., Riess H., Stieler J., et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J. Clin. Oncol. 2014; 32: 2423-9
  20. Von Hoff D.D., Ervin T., Arena F.P. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 2013; 369: 1691-703. [PMC free article]
  21. Herman J.M., Chang D.T., Goodman K.A., et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. 2015; 121: 1128-37. [PMC free article]
  22. Regine W.F., Winter K.A., Abrams R. et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann. Surg. Oncol. 2011; 18: 1319-26. [PMC free article]
  23. Hsu C.C., Herman J.M., Corsini M.M. et al. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann. Surg. Oncol. 2010; 17: 981-90. [PMC free article]
  24. Huguet F., Hammel P., Vernerey D. et al. Impact of chemoradiotherapy (CRT) on local control and time without treatment in patients with locally advanced pancreatic cancer (LAPC) included in the international phase III LAP 07 study. J. Clin. Oncol. 2014; 32(Suppl):4001.
  25. Schellenberg D., Goodman K.A., Lee F. et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiation therapy for locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 2008; 72: 678-86
  26. Valle J., Wasan H., Palmer D.H. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 2010; 362: 1273-81. doi: 10.1056/NEJMoa0908721.
  27. Lee J., Park S.H,. Chang H.M. et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012; 13: 181-8. doi: 10.1016/S1470-2045(11)70301-1
  28. Alexiades-Armenakas M. Laser-mediated photodynamic therapy. Clinics in Dermatology. 2006; 24 (1): 16-25.
  29. Zhao B., He Y. Y. Recent advances in the prevention and treatment of skin cancer using photodynamic therapy. Expert Review of Anticancer Therapy. 2010; 10 (11): 1797-809.
  30. Jerjes W., Upile T., Akram S., Hopper C. The surgical palliation of advanced head and neck cancer using photodynamic therapy. Clinical Oncology. 2010; 22 (9): 785-91.
  31. Wildeman M.A., Nyst H.J., Karakullukcu B., Tan B.I. Photodynamic therapy in the therapy for recurrent/persistent nasopharyngeal cancer. Head & Neck Oncology. 2009; 1: article 40.
  32. Chen M., Pennathur A., Luketich J.D. Role of photodynamic therapy in unresectable esophageal and lung cancer. Lasers in Surgery and Medicine. 2006; 38 (5): 396-402.
  33. Ducreux M., Cuhna A. Sa., Caramella C. et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2015; 26: 56-68.
  34. Yusuf T. E., Matthes K., Brugge W.R. EUS-guided photodynamic therapy with verteporfin for ablation of normal pancreatic tissue: a pilot study in a porcine model (with video). Gastrointestinal Endoscopy. 2008; 67 (6): 957-61.
  35. Leggett C.L., Gorospe E.C., Murad M.H. Montori V.M., Baron T.H., Wang K.K. Photodynamic therapy for unresectable cholangiocarcinoma: a comparative effectiveness systematic review and meta-analyses. Photodiagnosis Photodyn. Ther. 2012; 9:189-95.
  36. Lu Y., Liu L., Wu J.C., Bie L.K., Gong B. Efficacy and safety of photodynamic therapy for unresectable cholangiocarcinoma: a meta-analysis. Clin. Res. Hepatol. Gastroenterol. 2015; 39:718-24.
  37. Yang J., Shen H., Jin H., Lou Q., Zhang X. Treatment of unresectable extrahepatic cholangiocarcinoma using hematoporphyrin photodynamic therapy: a prospective study. Photodiagnosis Photodyn. Ther. 2016 doi: 10.1016/j.pdpdt.2016.10.001
  38. Jain S., Kockelbergh R.C. The role of photodynamic diagnosis in the contemporary management of superficial bladder cancer. BJU International. 2005; 96 (1): 17-21.
  39. Robertson C.A., Evans D.H., and Abrahamse H. Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT. Journal of Photochemistry and Photobiology B. 2009; 96 (1):1-8.
  40. Bown S.G., Rogowska A.Z., Whitelaw D.E. et al. Photodynamic therapy for cancer of the pancreas. Gut. 2002; 50 (4): 549-57.
  41. Tseng W.W., Saxton R.E., Deganutti A. and Liu C.D. Infrared laser activation of indocyanine green inhibits growth in human pancreatic cancer. Pancreas. 2003; 27 (3): e42- e45.
  42. Huggett M.T., Jermyn M., Gillams A. et al. Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. Br. J. Cancer. 2014; 110, 1698-704.
  43. Park D.H, Lee S.S, Park S.E. et al. Randomised phase II trial of photodynamic therapy plus oral fluoropyrimidine, S-1, versus photodynamic therapy alone for unresectable hilar cholangiocarcinoma. Eur. J. Cancer. 2014; 50: 1259-68.
  44. Wentrup R., Winkelmann N., Mitroshkin A. et al. Photodynamic therapy plus chemotherapy compared with photodynamic therapy alone in hilar nonresectable cholangiocarcinoma. Gut Liver. 2016; 10: 470-75.
  45. Xie Q., Jia L., Liu Y.H., Wei C.G. Synergetic anticancer effect of combined gemcitabine and photodynamic therapy on pancreatic cancer in vivo. World Journal of Gastroenterology. 2009; 15 (6): 737-41.
  46. National Comprehensive Cancer Network. NCCN Guidelines Version 2.2015. Pancreatic Adenocarcinoma. http://www.nccn.org.

Copyright (c) 2018 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies